Sign in Subscribe
Pharmaceutical industry

European Biotechnology Sector Faces Challenges Amidst Regulatory Headwinds

Strategic Insights

— 1 min read

The European biotechnology sector, despite witnessing significant investments and advancements in science, faces numerous challenges in bringing its products to market. According to Ernst & Young's 11th annual European Biotechnology report, a dearth of European biotech products has been observed, with only six drug approvals involving European biotechs in 2003. The report highlights the importance of clear product focus, regulatory, and reimbursement frontwork as crucial for the sector's success. Landmark scientific advances, like the cloning of Dolly the sheep, are not enough to guarantee commercial success, as seen in the case of PPL Therapeutics.

Key Takeaways:

  • The European biotechnology sector faces significant challenges in bringing its products to market, despite advances in science.
  • Only six drug approvals involving European biotechs were observed in 2003, a year marked by positive news flow.
  • Clear product focus, regulatory, and reimbursement frontwork are essential for sector success.
  • Landmark scientific advances, like the cloning of Dolly the sheep, do not guarantee commercial success.
  • Companies are cutting back on less promising early-stage products and shifting focus to later-stage candidates, either by organic growth or in-licensing.
  • Approvals are crucial for survival, with some firms in Europe doing well from the fuss, but critical to strengthen the sector.
  • The Orphan Drug Act has helped many biotechs onto the regulatory ladder but might run out of track.
  • The convergence of biotech and pharma has led to increased interest in personalized medicines initially classified as orphans.

Statistics:

  • 68 Phase III compounds are in trials as part of the European public company pipeline.
  • Based on reasonable attrition rates, around 15 new drugs, or one-fifth of the total, should make it to market over the next few years.
  • The FDA approved 25 biotech drugs in 2003, alongside 12 new indications.
  • The average approval time for biotechnology products via the EMEA and the FDA is around 17 months.
  • FDA approval for monoclonal antibody therapeutics appeared 41% faster than the EMEA.

Sources:

  • Ernst & Young, 11th annual European Biotechnology report
  • US Tufts Center for the Study of Drug Development
  • Marketletter, April 5, on EMEA budget and staff recruitment
  • Marketletters passim, on various company events, decisions, and developments
  • The Daily Telegraph, on Sir Michael Rawlings' criticism of EU policy and regulations

Read more